Building off of last year’s successful new format, AACE is pleased to announce the newest edition of the AACE Self-Assessment Program (ASAP)!


Learn how you can elevate your endocrinology career by participating in AACE consensus statements, guidelines, educational programs, abstracts, and more.


We're seeking chairs, authors, and a methodology fellow to help us develop a consensus statement on multiple endocrine neoplasia type 1 (MEN1). Learn how to apply today!


After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.


Joint Guidance on COVID-19 Vaccination and Osteoporosis Management from the American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinology (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), the International Osteoporosis Foundation (IOF), and the National Osteoporosis Foundation (NOF)  


Here is a round-up of four different online, on-demand courses you can take that will walk you through the guidelines and help you apply them to your practice.


August 18, 2020 (Latest Update)

COVID-19 Resources: Telehealth, Updates and More

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.


Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.


When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to AACE member Daniel L. Hurley, MD, FACE, who spoke at the AACE 28th Annual Scientific & Clinical Congress.


Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


Among patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28th Annual Scientific & Clinical Congress.


AACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28th Annual Scientific & Clinical Congress.